Benign prostatic hyperplasia (BPH) is a highly prevalent condition among aging men and a leading cause of lower urinary tract symptoms (LUTS). Each year, $4 billions was spent in USA on the healthcare of BPH patients. The steroid 5α-reductase type 2 (SRD5A2) is the key enzyme that regulates prostate development and growth. Clinically, 5α-reductase inhibitors (5ARIs) are commonly prescribed to reduce prostate volume by blocking DHT synthesis and dampening androgen-driven prostate growth. However, 5ARI such as finasteride reduces the progression of LUTS by only approximately 34%, suggesting that androgen-independent mechanisms may also contribute to prostate enlargement and therapeutic resistance.